Ramipril (ramipril): Reviews and patient testimonials

Ramipril 1.25 mg hard capsules

-Treatment of hypertension.

- Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

• diabetes with at least one cardiovascular risk factor.

- Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non-diabetic nephropathy as defined by macroproteinuria ≥ 3 g / day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 1.25mg Capsules

- Treatment of hypertension.

- Treatment of renal disease.

o Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

o Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

o Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 1.25mg Hard Capsules

• Treatment of hypertension.

• Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or • diabetes with at least one cardiovascular risk factor.

• Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria, • Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor, • Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

• Treatment of symptomatic heart failure.

• Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 10 mg hard capsules

-Treatment of hypertension.

- Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

• diabetes with at least one cardiovascular risk factor.

- Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non-diabetic nephropathy as defined by macroproteinuria ≥ 3 g / day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 10mg Capsules

- Treatment of hypertension.

- Treatment of renal disease.

o Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

o Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

o Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 10mg Hard Capsules

• Treatment of hypertension.

• Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or • diabetes with at least one cardiovascular risk factor.

• Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria, • Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor, • Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

• Treatment of symptomatic heart failure.

• Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 10mg Tablets

- Treatment of hypertension.

- Treatment of renal disease.

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 2.5 mg hard capsules

-Treatment of hypertension.

- Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

• diabetes with at least one cardiovascular risk factor.

- Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non-diabetic nephropathy as defined by macroproteinuria ≥ 3 g / day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 2.5mg Capsules

- Treatment of hypertension.

- Treatment of renal disease.

o Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

o Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

o Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 2.5mg Hard Capsules

• Treatment of hypertension.

• Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or • diabetes with at least one cardiovascular risk factor.

• Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria, • Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor, • Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

• Treatment of symptomatic heart failure.

• Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 2.5mg Tablets

- Treatment of hypertension.

- Treatment of renal disease.

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 2.5mg/5ml Oral Solution

• Treatment of hypertension.

• Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

- manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

- diabetes with at least one cardiovascular risk factor.

• Treatment of renal disease:

- Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria

- Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor

- Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥3 g/day.

• Treatment of symptomatic heart failure.

• Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 5 mg hard capsules

-Treatment of hypertension.

- Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or

• diabetes with at least one cardiovascular risk factor.

- Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non-diabetic nephropathy as defined by macroproteinuria ≥ 3 g / day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 5mg Capsules

- Treatment of hypertension.

- Treatment of renal disease.

o Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

o Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

o Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 5mg Hard Capsules

• Treatment of hypertension.

• Cardiovascular prevention: reduction of cardiovascular morbidity and mortality in patients with:

• manifest atherothrombotic cardiovascular disease (history of coronary heart disease or stroke, or peripheral vascular disease) or • diabetes with at least one cardiovascular risk factor.

• Treatment of renal disease:

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria, • Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor, • Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

• Treatment of symptomatic heart failure.

• Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Ramipril 5mg Tablets

- Treatment of hypertension.

- Treatment of renal disease.

• Incipient glomerular diabetic nephropathy as defined by the presence of microalbuminuria,

• Manifest glomerular diabetic nephropathy as defined by macroproteinuria in patients with at least one cardiovascular risk factor,

• Manifest glomerular non diabetic nephropathy as defined by macroproteinuria ≥ 3 g/day.

- Treatment of symptomatic heart failure.

- Secondary prevention after acute myocardial infarction: reduction of mortality from the acute phase of myocardial infarction in patients with clinical signs of heart failure when started > 48 hours following acute myocardial infarction.

Route of administration: Oral
Molecule: ramipril